Patient mortality and survival. United States Renal Data System. Am J Kidney Dis. 1998; 32(2 Suppl 1):S69-80.
Ritz E, Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis. 1996; 27.167-94
Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med. 1998; 158.134-40
Parving HH. Clinical experience in the treatment of diabetic renal disease (type 1 and 2): summary and concluding remarks. Kidney Int. 1994; 45.Suppl165-6
Parving HH, Rossing P, Hommel E, Schmidt UM. Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience. Am J Kidney Dis. 1995; 26.99-107
Bennett PH, Haffner S, Kasiske BL, Keane WF, Mogensen CE, Parving HH, et al.. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the scientific advisory board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis. 1995; 25.107-12
Kraft SK, Lazaridis EN, Qiu C, Clark CM Jr, Marrero DG. Screening and treatment of diabetic nephropathy by primary care physicians. J Gen Intern Med. 1999; 14.88-97
Weiner JP, Parente ST, Garnick DW, Fowles J, Lawthers AG, Palmer H. Variation in office-based quality. A claims-based profile of care provided to Medicare patients with diabetes. JAMA. 1995; 273.1503-8
Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992; 117.234-42
Donohoe JF, Kelly J, Laher MS, Doyle GD. Lisinopril in the treatment of hypertensive patients with renal impairment. Am J Med. 1988; 85.31-5
Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med. 1997; 102.43-9
Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation. 1997; 95.1085-90
Frank E. Enhancing patient outcomes: treatment adherence. J Clin Psychiatry. 1997; 58.Suppl 111-4
Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J. 1995; 130(3 Pt 1):572-9.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329.1456-62
Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993; 118.577-81
Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998; 128(12 Pt 1):982-8.
Niskanen LK, Penttila I, Parviainen M, Uusitupa MI. Evolution, risk factors, and prognostic implications of albuminuria in NIDDM. Diabetes Care. 1996; 19.486-93
Third National Health and Nutrition Examination Survey, 1988-1994, NHANES III Household Adult and Laboratory Data Files (CD-ROM). Public Use Data File Documentation Number 76200. Hyattsville, MD: U.S. Department of Health and Human Services. National Center for Health Statistics, Centers for Disease Control and Prevention; 1996.
Statistical Abstract of the United States: Life Expectancy. Washington, DC: U.S. Bureau of the Census; 1996.
Walters DP, Gatling W, Houston AC, Mullee MA, Julious SA, Hill RD. Mortality in diabetic subjects: an eleven-year follow-up of a community-based population. Diabet Med. 1994; 10.968-73
Drug Topics Red Book. Montvale, NJ: Medical Economics; 1998.
Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, et al.. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993; 13.89-102
Churchill DN, Torrance GW, Taylor DW, Barnes CC, Ludwin D, Shimizu A, et al.. Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin Invest Med. 1987; 10.14-20
Lovell HG. Are angiotensin-converting enzyme inhibitors useful for normotensive diabetic patients with microalbuminuria? [Review] The Cochrane Database of Systematic Reviews. 1998; 3.
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997; 20:1183-97.
Schwartz LM, Woloshin S. Changing disease definitions: implications for disease prevalence. analysis of the Third National Health and Nutrition Examination Survey, 1988-1994. Effective Clinical Practice. 1999; 2.76-85